These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 27872957)
41. Peterson LM; Kurland BF; Yan F; Jiresova AN; Gadi VK; Specht JM; Gralow JR; Schubert EK; Link JM; Krohn KA; Eary JF; Mankoff DA; Linden HM J Nucl Med; 2021 Feb; 62(2):184-190. PubMed ID: 32591490 [TBL] [Abstract][Full Text] [Related]
42. Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[ Wang M; Glick-Wilson BE; Zheng QH Appl Radiat Isot; 2020 Jun; 160():109109. PubMed ID: 32174461 [TBL] [Abstract][Full Text] [Related]
43. PET Imaging of Estrogen Receptors Using Kumar M; Salem K; Jeffery JJ; Fowler AM Methods Mol Biol; 2022; 2418():129-151. PubMed ID: 35119664 [TBL] [Abstract][Full Text] [Related]
44. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. van Kruchten M; Glaudemans AWJM; de Vries EFJ; Schröder CP; de Vries EGE; Hospers GAP Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1674-1681. PubMed ID: 26091705 [TBL] [Abstract][Full Text] [Related]
45. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. Liao GJ; Clark AS; Schubert EK; Mankoff DA J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345 [TBL] [Abstract][Full Text] [Related]
46. Salem K; Kumar M; Powers GL; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM Radiology; 2018 Mar; 286(3):856-864. PubMed ID: 28956736 [TBL] [Abstract][Full Text] [Related]
47. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. Goetz MP; Suman VJ; Reid JM; Northfelt DW; Mahr MA; Ralya AT; Kuffel M; Buhrow SA; Safgren SL; McGovern RM; Black J; Dockter T; Haddad T; Erlichman C; Adjei AA; Visscher D; Chalmers ZR; Frampton G; Kipp BR; Liu MC; Hawse JR; Doroshow JH; Collins JM; Streicher H; Ames MM; Ingle JN J Clin Oncol; 2017 Oct; 35(30):3391-3400. PubMed ID: 28854070 [TBL] [Abstract][Full Text] [Related]
48. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone. Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420 [TBL] [Abstract][Full Text] [Related]
49. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912 [TBL] [Abstract][Full Text] [Related]
50. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929 [TBL] [Abstract][Full Text] [Related]
51. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis. Evangelista L; Guarneri V; Conte PF Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910 [TBL] [Abstract][Full Text] [Related]
52. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes. Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512 [TBL] [Abstract][Full Text] [Related]
53. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model. Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898 [TBL] [Abstract][Full Text] [Related]
54. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT. van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534 [TBL] [Abstract][Full Text] [Related]
55. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006 [TBL] [Abstract][Full Text] [Related]
56. Prospective Pilot Study of Covington MF; Hoffman JM; Morton KA; Buckway B; Boucher KM; Rosenthal RE; Porretta JM; Brownson KE; Matsen CB; Vaklavas C; Ward JH; Wei M; Buys SS; Chittoria N; Yakish ED; Archibald ZG; Burrell LD; Butterfield RI; Yap JT AJR Am J Roentgenol; 2023 Aug; 221(2):228-239. PubMed ID: 36919879 [No Abstract] [Full Text] [Related]
57. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[ Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554 [TBL] [Abstract][Full Text] [Related]
58. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878 [TBL] [Abstract][Full Text] [Related]
59. Diagnostic accuracy and safety of 16α-[ Chae SY; Ahn SH; Kim SB; Han S; Lee SH; Oh SJ; Lee SJ; Kim HJ; Ko BS; Lee JW; Son BH; Kim J; Ahn JH; Jung KH; Kim JE; Kim SY; Choi WJ; Shin HJ; Gong G; Lee HS; Lee JB; Moon DH Lancet Oncol; 2019 Apr; 20(4):546-555. PubMed ID: 30846327 [TBL] [Abstract][Full Text] [Related]
60. Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US. Munter-Young R; Fuentes-Alburo A; DiGregorio N; Neeser K; Gultyaev D PLoS One; 2024; 19(5):e0302486. PubMed ID: 38743917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]